• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Intern Med . Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vacc

tetano

Editor, Senior Moderator
Intern Med


. 2022 Apr 9.
doi: 10.2169/internalmedicine.9199-21. Online ahead of print.
Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination


Yuta Baba[SUP] 1 [/SUP], Hirotaka Sakai[SUP] 1 [/SUP], Nobuyuki Kabasawa[SUP] 1 [/SUP], Hiroshi Harada[SUP] 1 [/SUP]



Affiliations

Abstract

Several vaccines have been developed for coronavirus disease 2019-caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-in record time. A few cases of immune thrombocytopenic purpura (ITP) following SARS-CoV-2 vaccination have been reported. We herein report a 90-year-old man who received the Pfizer-BioNTech SARS-CoV-2 vaccine (BNT162b2) and developed severe thrombocytopenia with intracranial hemorrhaging and duodenal bleeding, consistent with vaccine-related ITP. He was successfully treated with intravenous immunoglobulin, prednisolone, and eltrombopag and discharged without cytopenia. Vaccine-related ITP should be suspected in patients presenting with abnormal bleeding or purpura after vaccination.

Keywords: SARS-CoV-2 vaccine; bleeding; immune thrombocytopenic purpura.




Yuta Baba[SUP] 1 [/SUP], Hirotaka Sakai[SUP] 1 [/SUP], Nobuyuki Kabasawa[SUP] 1 [/SUP], Hiroshi Harada[SUP] 1 [/SUP]



Affiliations

Abstract

Several vaccines have been developed for coronavirus disease 2019-caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-in record time. A few cases of immune thrombocytopenic purpura (ITP) following SARS-CoV-2 vaccination have been reported. We herein report a 90-year-old man who received the Pfizer-BioNTech SARS-CoV-2 vaccine (BNT162b2) and developed severe thrombocytopenia with intracranial hemorrhaging and duodenal bleeding, consistent with vaccine-related ITP. He was successfully treated with intravenous immunoglobulin, prednisolone, and eltrombopag and discharged without cytopenia. Vaccine-related ITP should be suspected in patients presenting with abnormal bleeding or purpura after vaccination.

Keywords: SARS-CoV-2 vaccine; bleeding; immune thrombocytopenic purpura.
 
Back
Top Bottom